Day: October 12, 2022

Ahmed, Wasim; Huang, Zi-Hao; Cui, Zi-Ning; Tang, Ri-Yuan published the artcile< Design and synthesis of unique thiazoloisoquinolinium thiolates and derivatives>, Electric Literature of 90806-58-9, the main research area is thiazoloisoquinolinium thiolate preparation; isoquinoline ethylpropionate cycloaddition; alkylthio thiazoloisoquinolinium iodide preparation; alkyl halide thiazoloisoquinolinium thiolate nucleophilic substitution; epithiometheno thiazinoisoquinoline carboxylate preparation; terminal alkyne thiazoloisoquinolinium thiolate cycloaddition.

The synthesis of unique mesoionic thiazoloisoquinolinium thiolates stabilized by aromatization and 1,3-dipolarization. Herein, compounds were synthesized via the three component [2+2+1] cycloaddition reaction of isoquinolines with Et propionate and elemental sulfur in the absence of any metal catalyst and additives. Importantly, thiazoloisoquinolinium thiolates were transformed to thioether-containing thiazoloisoquinolinium halides. A selective [4+2] cycloaddition were also used to form S-bridged fused tetracyclic compounds with a thiothiamide ring unit and two quaternary carbon centers. Compound I showed good bioactivity against the chlorophyll of duckweed (Lemna minor) with inhibition rate of 51.5μg/mL.

Chinese Chemical Letters published new progress about [2+2+1] Cycloaddition reaction. 90806-58-9 belongs to class isoquinoline, and the molecular formula is C10H9NO, Electric Literature of 90806-58-9.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Zeng, Jia; Lytle, Anna K.; Gage, David; Johnson, Sean J.; Zhan, Jixun published the artcile< Specific chlorination of isoquinolines by a fungal flavin-dependent halogenase>, Related Products of 3336-49-0, the main research area is halogenase Rdc1 Pochonia isoquinoline specific chlorination; chloroisoquinoline biosynthesis halogenase Rdc1 Pochonia.

Rdc2 of Pochonia chlamydosporia is the 1st flavin-dependent halogenase identified from fungi. Based on the reported structure of the bacterial halogenase CmlS, the authors built a homol. model for Rdc2. The model suggested an open substrate binding site that was capable of binding the natural substrate, monocillin II, and possibly other mols. such as 4-hydroxyisoquinoline (I) and 6-hydroxyisoquinoline (II). In vitro and in vivo halogenation experiments confirmed that I and II could be halogenated at the position ortho to the OH group, leading to the synthesis of the chlorinated isoquinolines, 3-chloro-4-hydroxyisoquinoline and 5-chloro-6-hydroxyisoquinoline, resp., which further expanded the spectrum of identified substrates of Rdc2. This work revealed that Rdc2 is a useful biocatalyst for the synthesis of various halogenated compounds

Bioorganic & Medicinal Chemistry Letters published new progress about Pochonia chlamydosporia. 3336-49-0 belongs to class isoquinoline, and the molecular formula is C9H7NO, Related Products of 3336-49-0.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Fang, Zaixiang; Wang, Yi; Wang, Yuanhua published the artcile< Synthesis of 4-Iodoisoquinolin-1(2H)-ones by a Dirhodium(II)-Catalyzed 1,4-Bisfunctionalization of Isoquinolinium Iodide Salts>, HPLC of Formula: 90806-58-9, the main research area is iodoisoquinoline preparation; rhodium catalyst aerobic iodination oxidation alkylisoquinolinium iodide acetoxybenziodoxolone.

In the presence of Rh2(esp)2, N-alkylisoquinolinium iodides such as N-methylisoquinolinium iodide underwent aerobic iodination and oxidation with acetoxybenziodoxolone in MeOH at 50° to yield 4-iodo-1-isoquinolinones such as I. The method was used to prepare an intermediate in the synthesis of the CRTH2 antagonist CRA-680.

Organic Letters published new progress about Crystal structure. 90806-58-9 belongs to class isoquinoline, and the molecular formula is C10H9NO, HPLC of Formula: 90806-58-9.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Krapcho, A. Paul; Petry, Mary E.; Getahun, Zelleka; Landi, John J. Jr.; Stallman, John; Polsenberg, Johanna F.; Gallagher, Cynthia E.; Maresch, Martin J.; Hacker, Miles P. published the artcile< 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A Novel Class of Chromophore-Modified Antitumor Anthracene-9,10-diones: Synthesis and Antitumor Evaluations>, SDS of cas: 144511-13-7, the main research area is anthracenedione preparation antitumor; benzoisoquinoline preparation antitumor.

Synthetic procedures have been developed which lead to the 2-aza congeners I (R = amine groups or N-containing heterocyclic groups) and several related N-oxides (II, R = NH2 or NMe2). I exhibited a wide range of in vitro cytotoxicity against L1210 leukemia, the human colon adenocarcinoma cell line LoVo, and the doxorubicin resistant LoVo/DX cell line. Selected analogs of I showed significant P388 antileukemic activity in mice with I (R = NH2, n = 2) exhibiting high activity. This activity was also retained in the related N-oxide II (R = NH2, n = 2). These heterocyclic bioisosteric models are representative of the first anthracene-9,10-diones which display antileukemic activity comparable to mitoxantrone.

Journal of Medicinal Chemistry published new progress about Antitumor agents. 144511-13-7 belongs to class isoquinoline, and the molecular formula is C13H5F2NO2, SDS of cas: 144511-13-7.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Liang, Jun; Van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade S.; Chang, Christine; Delarosa, Donnie; De Voss, Jason; Driscoll, Jim; Eigenbrot, Charles; Goodacre, Simon; Ghilardi, Nico; MacLeod, Calum; Johnson, Adam; Bir Kohli, Pawan; Lai, Yingjie; Lin, Zhonghua; Mantik, Priscilla; Menghrajani, Kapil; Nguyen, Hieu; Peng, Ivan; Sambrone, Amy; Shia, Steven; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Williams, Karen; Wu, Lawren C.; Yang, Wenqian; Zhang, Birong; Magnuson, Steven published the artcile< Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model>, Synthetic Route of 552331-06-3, the main research area is imidazopyridine derivative preparation TYK2 inhibitor psoriasis; IL-23; Imidazopyridine; Kinase; Psoriasis; TYK2.

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.

Bioorganic & Medicinal Chemistry Letters published new progress about Antipsoriatic agents. 552331-06-3 belongs to class isoquinoline, and the molecular formula is C9H5BrClN, Synthetic Route of 552331-06-3.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Evison, Benny J.; Palmer, James T.; Lambert, Gilles; Treutlein, Herbert; Zeng, Jun; Nativel, Brice; Chemello, Kevin; Zhu, Qing; Wang, Jie; Teng, Yanfen; Tang, Wei; Xu, Yanfeng; Rathi, Anuj Kumar; Kumar, Sanjay; Suchowerska, Alexandra K.; Parmar, Jasneet; Dixon, Ian; Kelly, Graham E.; Bonnar, James published the artcile< A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove>, Safety of Isoquinolin-8-ylboronic acid, the main research area is cardiovascular disease PCSK9 LDL receptor cholesterol mall moleculep; Cardiovascular disease; LDL cholesterol; LDL receptor; Low density lipoprotein (LDL); Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9); Small molecule.

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low d. lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small mol. inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavorable for binding by small organic mols. Despite its challenging nature, we report herein the discovery of compound 3f as a small mol. inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chem., 3f emerged as a lead-like mol. by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered s.c. in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small mol. inhibitor against PCSK9 is therapeutically viable.

Bioorganic & Medicinal Chemistry published new progress about Bioavailability. 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Safety of Isoquinolin-8-ylboronic acid.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Chilamari, Maheshwerreddy; Immel, Jacob R.; Bloom, Steven published the artcile< General Access to C-Centered Radicals: Combining a Bioinspired Photocatalyst with Boronic Acids in Aqueous Media>, HPLC of Formula: 721401-43-0, the main research area is radical preparation photocatalyzed oxidation boronic acid catalyst reaction mechanism; conjugate addition reaction radical Michael acceptor.

Carbon-centered radicals are indispensable building blocks for modern synthetic chem. In recent years, visible light photoredox catalysis has become a promising avenue to access C-centered radicals from a broad array of latent functional groups, including boronic acids. Herein, we present an aqueous protocol wherein water features a starring role to help transform aliphatic, aromatic, and heteroaromatic boronic acids to C-centered radicals with a bioinspired flavin photocatalyst. These radicals are used to deliver a diverse pool of alkylated products, including three pharmaceutically relevant compounds, via open-shell conjugate addition to disparate Michael acceptors. The mechanism of the reaction is investigated by computational studies, deuterium labeling, radical-trapping experiments, and spectroscopic anal.

ACS Catalysis published new progress about Alkylation (deborylative-alkylation). 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, HPLC of Formula: 721401-43-0.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem